← Leaderboards
David L. McCormick
Iit Research Institute
$9,946,066
Attributed
$17,752,196
Total exposure
18
Grants
3
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.
Funding over time
peak $3.4M · FY2014–25$5M$3.8M$2.5M$1.3M$0
'14
'15
'16
'17
'18
'19
'20
'21
'22
'23
'24
'25
Funding mix
By agency
NIH$17,752,196 · 18
By mechanism
UH3$7,175,778 · 2
UH2$6,783,112 · 2
N01$3,793,306 · 14
Top collaborators
- Nanduri R Prabhakar5 shared
- Julian Solway5 shared
- Pavel A Petukhov2 shared
- Gregory R J Thatcher2 shared
Others in their field
Top investigators on “Toxicology”
- Leonard Freedman · Leidos Biomedical Research, Inc.$239,520,687
- David Heimbrook · Leidos Biomedical Research, Inc.$155,080,196
- Barney Sparrow · Battelle Memorial Institute$96,886,832
- Lynn Briscoe · Leidos Biomedical Research, Inc.$93,294,869
- Robert H Vonderheide · University Of Pennsylvania$78,967,264
- Reshan Fernando · Research Triangle Institute$70,521,464
Research focus
ToxicologyCanis FamiliarisPre-ClinicalRattusClinical TrialsToxic EffectPharmacy (Field)MedicineSafetyPropertyBreathingMetabolismPharmaceutical PreparationsPharmacologic SubstanceInhibitor/AntagonistIn VivoDoseDrug KineticsLeadFundingBaseIn VitroDrug Screening /EvaluationPrevent
Grant awards (27)
Toxicology Studies on Compound MTX-531$451,034
N01 · FY2025 · CA · contact PI
PRECLINICAL TOXICOLOGY OF LARGE MOLECULE DRUGS DEVELOPED FOR CANCER AND OTHER AND OTHER INDICATIONS INDICATIONS$10,025
N01 · FY2025 · CA · contact PI
TOXICOLOGY STUDIES IN MICE AND DOGS ADMINISTERED MTX-531$1,339,008
N01 · FY2024 · CA · contact PI
PRECLINICAL TOXICOLOGY OF LARGE MOLECULE DRUGS DEVELOPED FOR CANCER AND OTHER AND OTHER INDICATIONS INDICATIONS$375,416
N01 · FY2024 · CA · contact PI
Contract Orientation and Kickoff Meeting$9,383
N01 · FY2024 · CA · contact PI
Therapeutic Targeting of Carotid Body Chemoreflex for Sleep Disordered Breathing$1,860,742
UH3 · FY2018 · HL
Preclinical development of myosolvins, a new class of medicine for asthma$198,123
UH3 · FY2018 · HL
Therapeutic Targeting of Carotid Body Chemoreflex for Sleep Disordered Breathing$1,716,511
UH3 · FY2017 · HL
Preclinical development of myosolvins, a new class of medicine for asthma$1
UH3 · FY2017 · HL
Preclinical development of myosolvins, a new class of medicine for asthma$1,708,130
UH3 · FY2016 · HL
Therapeutic Targeting of Carotid Body Chemoreflex for Sleep Disordered Breathing$1,692,271
UH3 · FY2016 · HL
Preclinical development of myosolvins, a new class of medicine for asthma$1,714,997
UH2 · FY2015 · HL
Therapeutic Targeting of Carotid Body Chemoreflex for Sleep Disordered Breathing$1,643,080
UH2 · FY2015 · HL
Preclinical development of myosolvins, a new class of medicine for asthma$1,761,373
UH2 · FY2014 · HL
Therapeutic Targeting of Carotid Body Chemoreflex for Sleep Disordered Breathing$1,663,662
UH2 · FY2014 · HL
CHEMOPREVENTION WITH RODENT MODELS OF HEAD &NECK TUMORS$0
N01 · FY2001 · CN
PRECLINICAL TOXICOLOGY &PHARMACOLOGY OF DRUGS DEVELOPED$426,382
N01 · FY2000 · CM
AN ORAL CARCINOGENICITY STUDY IN P53 (+/-) MICE - (TASK$328,687
N01 · FY2000 · CN
EFFICACY STUDIES OF CHEMOPREVENTIVE AGENTS IN ANIMAL MOD$293,976
N01 · FY2000 · CN
'IN VITRO SCREENING OF SELECTED CHEMOPREVENTIVE AGENTS U$247,187
N01 · FY2000 · CN
RANGE FINDING/ACUTE ORAL TOXICITY OF CHEMOPREVENTIVES$175,243
N01 · FY2000 · CN
PRECLINICAL TOXICOLOGY &PHARMACOLOGY OF DRUGS DEVELOPED$100,000
N01 · FY2000 · CM
PRECLINICAL TOXICOLOGY (WS#52) -CHRONIC ORAL TOXICITY S$36,965
N01 · FY2000 · CN
PRECLINICAL TOXICOLOGY OF CHEMOPREVENTIVE AGENTS$0
N01 · FY2000 · CN
13 WEEK ORAL TOXICITY STUDIES OF TWO CHEMOPREVENTIVES$0
N01 · FY2000 · CN
INHIBITION OF SENCAR MOUSE BENZO(A)PYRENE SKIN PAINT$0
N01 · FY2000 · CN
CHEMOPREVENTIVE AGENT EFFICACY USING CHEMICALLY INDUCED$0
N01 · FY2000 · CN